Animals studies for neuroprotection in glaucoma have produced some promising results.
Glaucoma 360: Eyedrop targets and reduces episcleral venous pressure in glaucoma
February 8th 2023Thurein Htoo, MS, MBA, CEO and co-founder of Qlaris Bio, took the podium at the New Horizons Forum at the Glaucoma 360 conference in San Francisco to discuss the performance of the company’s episcleral venous pressure eyedrop, QLS-111.
Glaucoma 360: Glaucoma Progression from Hypotension
February 4th 2023Ruth Williams, MD, explained the importance of hypotension in glaucoma and its potential as a modifiable risk factor at the 27th annual Glaucoma Symposium during Glaucoma 360 at the Westin St. Francis San Francisco on Union Square.
2 Clarke Drive
Cranbury, NJ 08512